Long-term human response following subretinal injection of recombinant adenoassociated virus-sFlt-1 vector

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1010405

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Age-related Macular Degeneration (AMD) is the major cause of blindness in the developed world. The present best practice for treating wet AMD is monthly injections of Lucentis� into the eye which is expensive, inconvenient for the patient and has increased risk of infection. The additional assays associated with the clinical trial will test whether adeno-associated virus-mediated gene therapy is safe and whether it can eliminate the need of multiple injections while delivering the same outcome.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $373,076.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

gene therapy | immune response | immunology | macular degeneration | safety | vision

Related Links